Beese Fulmer Investment Management Inc. Grows Position in Eli Lilly and Company $LLY

Beese Fulmer Investment Management Inc. increased its holdings in Eli Lilly and Company (NYSE:LLY) by 49.8% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 4,864 shares of the company’s stock after buying an additional 1,616 shares during the quarter. Beese Fulmer Investment Management Inc.’s holdings in Eli Lilly and Company were worth $3,712,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Nemes Rush Group LLC lifted its holdings in Eli Lilly and Company by 2.5% in the third quarter. Nemes Rush Group LLC now owns 15,267 shares of the company’s stock valued at $11,649,000 after acquiring an additional 369 shares during the period. RiverPark Advisors LLC grew its stake in shares of Eli Lilly and Company by 5.4% during the 3rd quarter. RiverPark Advisors LLC now owns 4,296 shares of the company’s stock valued at $3,278,000 after purchasing an additional 220 shares during the period. DE Burlo Group Inc. grew its stake in shares of Eli Lilly and Company by 50.0% during the 3rd quarter. DE Burlo Group Inc. now owns 42,788 shares of the company’s stock valued at $32,647,000 after purchasing an additional 14,260 shares during the period. Mackenzie Financial Corp increased its position in shares of Eli Lilly and Company by 16.7% during the 3rd quarter. Mackenzie Financial Corp now owns 261,298 shares of the company’s stock valued at $199,370,000 after purchasing an additional 37,425 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Eli Lilly and Company by 1.5% in the 3rd quarter. Franklin Resources Inc. now owns 4,840,188 shares of the company’s stock worth $3,693,063,000 after purchasing an additional 73,323 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,000.30 on Wednesday. The company has a market capitalization of $943.64 billion, a price-to-earnings ratio of 43.59, a PEG ratio of 1.17 and a beta of 0.40. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The stock’s 50-day simple moving average is $1,042.64 and its 200-day simple moving average is $946.71. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter last year, the company earned $5.32 EPS. The firm’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: LLY is reportedly set to launch an oral obesity GLP‑1 in Q2, which would expand the market beyond injectables and support long‑term sales growth. Eli Lilly Set to Launch Oral Obesity Drug
• Positive Sentiment: The company launched an Employer Connect platform to broaden employer-sponsored access to obesity treatments, potentially increasing uptake and reducing access friction. Employer Connect Platform
• Positive Sentiment: Distribution gains: Amazon Pharmacy expanded access to LLY’s Zepbound KwikPen, improving retail availability and convenience for patients. Wider distribution should aid sales growth. Amazon Pharmacy Expands Access
• Positive Sentiment: Strategic and analyst support: LLY plans a $500M investment in South Korea’s biotech sector and J.P. Morgan reiterated a Buy rating — both signal management’s growth push and continued analyst confidence. South Korea Investment J.P. Morgan Keeps Buy Rating
• Neutral Sentiment: Macro/sector flow: crude-driven market moves and geopolitical tensions (Iran) have triggered sector rotation into aerospace and biopharma volatility; this broader rotation contributed to intraday pressure on LLY alongside other large-cap names. Sector Rotation Amid Geopolitics
• Negative Sentiment: Medicare coverage uncertainty: Eli Lilly warned some basic Medicare plans may not adhere to the $50/month out‑of‑pocket cap for weight‑loss drugs under the CMS model — this could complicate access and payer economics in the near term. Medicare Cap Warning
• Negative Sentiment: Legal risk: a U.S. court certified a nationwide class of third‑party payors in racketeering litigation tied to the older diabetes drug Actos, spotlighting potential liability and cash‑flow/legal exposure. Actos Class Action

Wall Street Analyst Weigh In

A number of research firms recently issued reports on LLY. Zacks Research downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Royal Bank Of Canada initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price target on the stock. National Bank Financial set a $1,286.00 price target on shares of Eli Lilly and Company in a research note on Monday, December 1st. Rothschild & Co Redburn boosted their price objective on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research report on Monday, January 26th. Finally, Guggenheim upped their price objective on Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,229.59.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.